Johnson & Johnson reported Q1 FY 2016 earnings of $1.68 per share (versus $1.56 in Q1 FY 2015), beating analysts' consensus of $1.65.

The company's quarterly revenues amounted to $17.482 bln (+0.60% y/y), almost in-line with analysts' consensus estimate of $17.491 bln.

Johnson & Johnson also issued guidance for FY16, raising EPS to $6.53-6.68 from previously expected $6.43-6.58 (versus analysts' consensus of $6.53) and revenues to $71.2-71.9 bln from previously expected $70.8-71.5 bln (versus analysts' consensus of $71.54 bln).

JNJ rose to $112.50 (+1.42%) in pre-market trading.